Overdosage: hemorrhagic complications.
Adverse Drug Reaction:
(common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia.
(uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Dalteparin. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Dalteparin. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dalteparin. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Dalteparin is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Dalteparin. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dalteparin. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Obinutuzumab. |
| Rivaroxaban | Dalteparin may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Dalteparin. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dalteparin. |
| Urokinase | Urokinase may increase the anticoagulant activities of Dalteparin. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Dalteparin. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Dalteparin. |
| Trandolaprilat | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Dalteparin. |
| Moexiprilat | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Dalteparin. |
| Cilazaprilat | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Dalteparin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Dalteparin. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Dalteparin. |
| Quinine | The therapeutic efficacy of Dalteparin can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Dalteparin can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Dalteparin. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Dalteparin. |
| Corticorelin ovine triflutate | The risk or severity of hypotension and sinus node depression can be increased when Dalteparin is combined with Corticorelin ovine triflutate. |
| Oritavancin | The therapeutic efficacy of Dalteparin can be decreased when used in combination with Oritavancin. |
| Streptokinase | Streptokinase may increase the anticoagulant activities of Dalteparin. |
| Telavancin | The therapeutic efficacy of Dalteparin can be decreased when used in combination with Telavancin. |
| Palifermin | The serum concentration of Palifermin can be increased when it is combined with Dalteparin. |
| Pentoxifylline | The therapeutic efficacy of Dalteparin can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Dalteparin. |
| Levocarnitine | The therapeutic efficacy of Dalteparin can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Dalteparin. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Dalteparin. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Dalteparin. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Dalteparin. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Dalteparin. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Dalteparin. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Dalteparin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dalteparin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Dalteparin. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Dalteparin. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Dalteparin. |
| Equol | Equol may decrease the anticoagulant activities of Dalteparin. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Dalteparin. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Dalteparin. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Dalteparin. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Dalteparin. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Dalteparin. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Dalteparin. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Dalteparin. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Dalteparin. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Dalteparin. |
| Estriol | Estriol may decrease the anticoagulant activities of Dalteparin. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Dalteparin. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Dalteparin. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Dalteparin. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dalteparin. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Dalteparin. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dalteparin. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Dalteparin. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Dalteparin. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Dalteparin. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Dalteparin. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Dalteparin. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Dalteparin. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Dalteparin. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dalteparin. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dalteparin. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Dalteparin. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Dalteparin. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Dalteparin. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dalteparin. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Dalteparin. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Dalteparin. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dalteparin. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Dalteparin. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Dalteparin. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Dalteparin. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Dalteparin. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Dalteparin. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Dalteparin. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Dalteparin. |
| Olsalazine | The risk or severity of bleeding can be increased when Dalteparin is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Dalteparin. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Dalteparin. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Dalteparin. |